Slide 1: Second Quarter Fiscal Year 2013 Conference Call and Webinar
Simulations Plus, Inc. (NASDAQ:SLP) Second Quarter Fiscal Year 2013 Conference Call and Webinar April 10, 2013
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such
Slide 3: SLP 2Q13 Highlights
• 2 Q13 compared to 2Q12: – 22nd consecutive profitable quarter, and 44 th of last 46 quarters – Sales up 11.8% to Record for any Quarter $3.118 million from $2.789 million – Gross profit up 9.5% to $2.619 million from $2.393 million – SG&A decreased 10.6% to $0.855 million from $0.956 million • As
Slide 4: Income Statement 2QFY13 vs 2QFY12
Income Statement 2QFY13 vs 2QFY12 ($ millions) 2Q13 2Q12 Net sales 3.118 2.789 Gross profit 2.619 2.393 Gross profit margin 84.0% 85.8% SG&A 0.855 0.956 R&D 0.248 0265 Total operating expenses 1.103 1.221 Income from continuing operations 1.517 1.172 Other income 0.055 0.088 Income from discontinued
Slide 5: Revenues by Quarter
Revenues by Quarter (pro forma prior to 2012) $1.4 $1.8 $2.0 $1.1 $1.7 $2.2 $2.3 $1.3 $2.1 $2.6 $2.6 $1.4 $2.2 $2.8 $2.8 $1.6 $2.3 $3.1 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013
Slide 6: Gross Profit by Fiscal Quarter
Gross Profit by Fiscal Quarter (pro forma prior to 2012) $1.24 $1.53 $1.75 $0.71 $1.45 $1.93 $1.97 $1.07 $1.70 $2.21 $2.21 $1.12 $1.90 $2.39 $2.33 $1.32 $1.90 $2.62 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013
Slide 7: EBITDA by Fiscal Quarter
EBITDA by Fiscal Quarter $0.55 $0.73 $0.93 $0.20 $0.73 $1.28 $1.23 $0.36 $1.00 $1.48 $1.48 $0.33 $1.11 $1.33 $1.40 $0.55 $1.09 $1.57 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013
Slide 8: Net Income by Quarter
Net Income by Quarter (pro forma prior to 2012) $0.33 $0.47 $0.53 $0.17 $0.44 $0.85 $0.74 $0.21 $0.56 $0.91 $1.05 $0.17 $0.76 $0.84 $0.87 $0.35 $0.59 $1.06 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013
Slide 9: New Customers by Quarter
New Customers by Quarter 10 11 9 9 14 17 12 14 15 21 13 10 18 18 Q1 Q2 Q3 Q4 2010 2011 2012 2013
Slide 10: Selected Balance Sheet Items
Selected Balance Sheet Items ($ millions) February 28, 2013 August 31, 2012 Cash and cash equivalents $9.755 $12.701 Cash per share 0.60 0.79 Total current assets 12.759 14.670 Total assets 15.642 17.347 Total current liabilities 0.844 1.415 Total liabilities 1.721 2.204 Current ratio 15.1 10.4 Shar
Slide 11: Returning Cash to Shareholders
$1.59 $0.80 $0.80 $2.24 $0.00 $0.00 $1.97 $12.66 $13.24 $12.89 $12.70 $11.38 $9.33 $9.76 $10.60 Q4FY11 Q1FY12 Q2FY12 Q3FY12 Q4FY12 Q1FY13 Q2FY13 10-Apr-13 $ Millions Dividend Paid Proceeds from Sale of Subsidiary Cash Returning Cash to Shareholders
Slide 12: Simulations Plus Products & Services
N H O OH O CH 3 CH 3 CH 3 Discovery Preclinical Clinical MedChem Studio™ MedChem Designer™ GastroPlus™ DDDPlus™ ADMET Predictor™ Simulations Plus Products & Services Consulting Services & Collaborations MembranePlus ™
Slide 13: Product News
Product News • Version 8.5 in final testing – release expected April 2013 • Unique precipitation model added • Infant PBPK physiologies added – pediatrics is high - interest area in FDA and industry • Added a built - in method for transporter in vitro - in vivo extrapolation • Added a number of addi
Slide 14: Marketing and Sales Program
Marketing and Sales Program • Conferences /Scientific Meetings continue to be primary source of leads • During Q2 we did 5 conferences in the U.S . and Europe • We presented one scientific poster • Trainings and Workshops • Hosted 3 - day GastroPlus workshop at the FDA for over 30 scientists • Condu
Slide 15: FDA Food Safety Research Collaboration
FDA Food Safety Research Collaboration • Completed the first year of a 5 - year renewable Research Collaboration Agreement (RCA) with Center for Food Safety and Applied Nutrition (CFSAN) to provide model - building capabilities for a large number (>70,000) of substances that can be in foods as addit
Slide 16: NCE (New Chemical Entity) Project
NCE (New Chemical Entity) Project • Highly successful malaria NCE project demonstrated the value of Simulations Plus software and consulting services for new molecule design • Seven molecules were received from synthesis and were tested against the malaria parasite. All seven showed inhibition of th
Slide 17: Summary
Summary • For 2QFY13: - Record financial performance continues our 5 - year - plus profitable trend - Earnings growth 26.5% on 11.8% revenue growth demonstrates high margins • Continuing to Expand our Life Sciences team: - One new IT engineer hired and one new Ph.D. to start in May, another in Octob
Slide 18: Q&A
Q&A